PFNX - Pfenex Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.14
-0.09 (-4.04%)
At close: 4:00PM EST

2.14 0.00 (0.00%)
After hours: 4:57PM EST

Stock chart is not supported by your current browser
Previous Close2.23
Open2.25
Bid1.97 x 100
Ask5.24 x 200
Day's Range2.10 - 2.26
52 Week Range2.07 - 9.79
Volume60,949
Avg. Volume99,664
Market Cap50.393M
Beta4.18
PE Ratio (TTM)N/A
EPS (TTM)-1.78
Earnings DateMar 13, 2018 - Mar 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.00
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEventslast month

    Edited Transcript of PFNX earnings conference call or presentation 9-Nov-17 9:30pm GMT

    Q3 2017 Pfenex Inc Earnings Call

  • Capital Cubelast month

    ETFs with exposure to Pfênex, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pfênex, Inc. Here are 5 ETFs with the largest exposure to PFNX-US. Comparing the performance and risk of Pfênex, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswirelast month

    Pfenex Inc. to Present at the Jefferies 2017 London Healthcare Conference

    SAN DIEGO , Nov. 9, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE AMERICAN: PFNX), announced today that it will be presenting at the Jefferies 2017 London Healthcare Conference on Wednesday, November 15 th at ...

  • Pfenex Reports Third Quarter 2017 Results, Interim PK data from PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update
    PR Newswirelast month

    Pfenex Reports Third Quarter 2017 Results, Interim PK data from PF708 Study, Completion of Process Development Milestone on Jazz Program and Provides Business Update

    SAN DIEGO , Nov. 9, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) is a clinical-stage biotechnology company developing complex therapeutic proteins. Using the patented Pfenex Expression Technology ...

  • ACCESSWIRElast month

    Pfenex, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Pfenex, Inc. (NYSE: PFNX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 9, 2017 at 4:30 PM Eastern Time. To ...

  • PR Newswire2 months ago

    Pfenex to Report Third Quarter 2017 Results and Provide Business Update on Thursday, November 9, 2017

    SAN DIEGO , Oct. 30, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its third quarter 2017 financial results will be released on Thursday, November 9, 2017 , after the market close. ...

  • Capital Cube2 months ago

    ETFs with exposure to Pfênex, Inc. : October 16, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pfênex, Inc. Here are 5 ETFs with the largest exposure to PFNX-US. Comparing the performance and risk of Pfênex, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to Pfênex, Inc. : September 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pfênex, Inc. Here are 5 ETFs with the largest exposure to PFNX-US. Comparing the performance and risk of Pfênex, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Pfênex, Inc. :PFNX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017
    Capital Cube3 months ago

    Pfênex, Inc. :PFNX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 27, 2017

    Categories: Yahoo FinanceGet free summary analysis Pfênex, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Pfênex, Inc. – China Biologic Products Holdings, Inc., Genocea Biosciences, Inc., Affimed N.V. and Epizyme, Inc. (CBPO-US, GNCA-US, AFMD-US and EPZM-US) that have also reported for this period. Highlights ... Read more (Read more...)

  • PR Newswire3 months ago

    Pfenex To Present at the Cantor Fitzgerald Global Healthcare Conference on September 27th, 2017

    SAN DIEGO , Sept. 19, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that it will be presenting at the Cantor Fitzgerald Global Healthcare Conference on September 27 th , 2017 at 4:00 ...

  • PR Newswire3 months ago

    Pfenex Announces Management Changes

    SAN DIEGO, Sept. 7, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), today announced that Dr. Paul Wagner, Chief Financial Officer, is leaving the Company effective October 13, 2017 to assume another position in industry. Pfenex is conducting an executive search for a replacement CFO. Additionally, Steve Sandoval, Chief Manufacturing Officer, is leaving the Company effective September 8, 2017, to pursue other opportunities.

  • PR Newswire3 months ago

    Pfenex Reports New Employment Inducement Award Under NYSE MKT Listing Rules

    SAN DIEGO, Sept. 1, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) ("Pfenex" or the "Company"), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high-value and difficult to manufacture proteins, today reported, as required by the NYSE MKT Company Guide, an equity inducement award to Eef Schimmelpennink, the Company's new Chief Executive Officer, President, and Secretary, who officially commenced employment with the Company on August 3, 2017. The stock option was granted to Mr. Schimmelpennink pursuant to the Pfenex Inc. 2016 Inducement Equity Incentive Plan, which was approved by the Company's board of directors under Rule 711(a) and the other relevant rules of the NYSE MKT Company Guide for equity grants to induce new employees to enter into employment with the Company.

  • PR Newswire4 months ago

    Pfenex To Present at the 19th Annual Rodman and Renshaw Global Investment Conference on September 12th, 2017

    SAN DIEGO , Aug. 29, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that it will be presenting at the 19 th Annual Rodman and Renshaw Global Investment Conference on September 12 th ...

  • PR Newswire4 months ago

    Pfenex To Present at the 6th Annual Liolios Gateway Conference on September 6th, 2017

    SAN DIEGO , Aug. 23, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that it will be presenting at the 6 th Annual Liolios Gateway Conference on September 6 th , 2017 at 11:00 am PT . ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of PFNX earnings conference call or presentation 9-Aug-17 8:30pm GMT

    Q2 2017 Pfenex Inc Earnings Call

  • Pfenex Reports Second Quarter 2017 Results and Provides Business Update
    PR Newswire4 months ago

    Pfenex Reports Second Quarter 2017 Results and Provides Business Update

    SAN DIEGO , Aug. 9, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to ...

  • PR Newswire4 months ago

    Pfenex Names Eef Schimmelpennink Chief Executive Officer

    SAN DIEGO, Aug. 3, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to manufacture proteins, today announced the appointment of Evert (Eef) Schimmelpennink as Chief Executive Officer, President, and Secretary effective August 3, 2017. Mr. Schimmelpennink was also appointed to serve as a Class III member of the board of directors effective August 3, 2017. Patrick Lucy, who held the post of Interim Chief Executive Officer, President, and Secretary will continue in his role as Chief Business Officer.

  • PR Newswire5 months ago

    Pfenex To Report Second Quarter 2017 Results and Provide Business Update on Wednesday, August 9, 2017

    SAN DIEGO , July 25, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its second quarter 2017 financial results will be released on Wednesday August 9, 2017 , after the market close.  ...

  • Capital Cube5 months ago

    ETFs with exposure to Pfênex, Inc. : July 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pfênex, Inc. Here are 5 ETFs with the largest exposure to PFNX-US. Comparing the performance and risk of Pfênex, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube6 months ago

    ETFs with exposure to Pfênex, Inc. : June 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pfênex, Inc. Here are 5 ETFs with the largest exposure to PFNX-US. Comparing the performance and risk of Pfênex, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • PR Newswire6 months ago

    Pfenex to Present at the 2017 JMP Healthcare Conference

    SAN DIEGO, June 8, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to ...

  • Capital Cube6 months ago

    ETFs with exposure to Pfênex, Inc. : June 2, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Pfênex, Inc. Here are 5 ETFs with the largest exposure to PFNX-US. Comparing the performance and risk of Pfênex, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Pfênex, Inc. :PFNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 1, 2017
    Capital Cube6 months ago

    Pfênex, Inc. :PFNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 1, 2017

    Categories: Yahoo FinanceGet free summary analysis Pfênex, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Pfênex, Inc. – China Biologic Products, Inc., Genocea Biosciences, Inc., Affimed N.V. and Epizyme, Inc. (CBPO-US, GNCA-US, AFMD-US and EPZM-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)

  • Thomson Reuters StreetEvents7 months ago

    Edited Transcript of PFNX earnings conference call or presentation 8-May-17 8:30pm GMT

    Q1 2017 Pfenex Inc Earnings Call

  • Pfenex Reports First Quarter 2017 Results and Provides Business Update
    PR Newswire7 months ago

    Pfenex Reports First Quarter 2017 Results and Provides Business Update

    SAN DIEGO, May 8, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, including high value and difficult to ...